Comparison between Aptus Pharma IPO and Earkart IPO.
Aptus Pharma IPO is a SME Fixed Price IPO proposed to list at BSE SME while Earkart IPO is a SME Fixed Price proposed to list at BSE SME.
| Aptus Pharma IPO | Earkart IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Fixed Price |
| Listing At | BSE SME | BSE SME |
| Lead Managers | Interactive Financial Services Ltd. | Sarthi Capital Advisors Pvt.Ltd. |
| Registrar | Bigshare Services Pvt.Ltd. | Skyline Financial Services Pvt.Ltd. |
| Market Maker | Market-Hub Stock Broking Pvt.Ltd. | Rikhav Securities Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Aptus Pharma IPO is up to ₹12.36 Cr whereas the issue size of the Earkart IPO is up to ₹46.76 Cr. The final issue price of Aptus Pharma IPO is ₹70.00 per share and of Earkart IPO is ₹135.00 per share.
| Aptus Pharma IPO | Earkart IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹65.00 per share | |
| Issue Price (Upper) | ₹70.00 per share | |
| Issue Price (Final) | ₹70.00 per share | ₹135.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 2000 shares | 1000 shares |
| Fresh Issue Size | 17,66,000 shares | 31,30,000 shares |
| Fresh Issue Size (Amount) | up to ₹12.36 Cr | up to ₹42.26 Cr |
| OFS Issue Size | 0 shares | 3,34,000 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹4.51 Cr |
| Issue Size Total | 17,66,000 shares | 34,64,000 shares |
| Issue Size Total (Amount) | up to ₹12.36 Cr | up to ₹46.76 Cr |
Aptus Pharma IPO opens on Sep 23, 2025, while Earkart IPO opens on Sep 25, 2025. The closing date of Aptus Pharma IPO and Earkart IPO is Sep 25, 2025, and Sep 29, 2025, respectively.
| Aptus Pharma IPO | Earkart IPO | |
|---|---|---|
| Anchor Bid Date | Sep 22, 2025 | |
| Issue Open | Sep 23, 2025 | Sep 25, 2025 |
| Issue Close | Sep 25, 2025 | Sep 29, 2025 |
| Basis Of Allotment (Tentative) | Sep 26, 2025 | Sep 30, 2025 |
| Initiation of Refunds (Tentative) | Sep 29, 2025 | Oct 01, 2025 |
| Credit of Share (Tentative) | Sep 29, 2025 | Oct 01, 2025 |
| Listing date (Tentative) | Sep 30, 2025 | Oct 03, 2025 |
| Anchor Lockin End date 1 | Oct 26, 2025 | |
| Anchor Lockin End date 2 | Dec 25, 2025 |
Aptus Pharma IPO P/E ratio is 11.29, as compared to Earkart IPO P/E ratio of 20.48.
| Aptus Pharma IPO | Earkart IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Aptus Pharma Ltd.'s revenue increased by 38% and profit after tax (PAT) rose by 288% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)Earkart Ltd.'s revenue increased by 35% and profit after tax (PAT) rose by 125% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 100 | 78.75 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 72.89 | 57.34 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 11.29 | 20.48 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹48.02 Cr. | ₹185.68 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 44.50% | 34.55% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 45.66% | 47.32% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.49 | 0.26 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹6.20 | ₹6.59 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 44.50% | 34.55% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Aptus Pharma IPO Retail Individual Investors (RII) are offered 6,20,000 shares while in Earkart IPO retail investors are offered 6,20,000 shares. Qualified Institutional Buyers (QIB) are offered 3,52,000 shares in Aptus Pharma IPO and 0 shares in Earkart IPO.
| Aptus Pharma IPO | Earkart IPO | |
|---|---|---|
| Anchor Investor Reservation | 5,28,000 shares | 0 shares |
| Market Maker Reservation | 94,000 shares | 1,85,000 shares |
| QIB | 3,52,000 shares | 0 shares |
| NII | 2,66,000 shares | 17,32,000 shares |
| RII | 6,20,000 shares | 17,32,000 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 17,66,000 shares | 34,64,000 shares |
Aptus Pharma IPO subscribed 22.27x in total, whereas Earkart IPO subscribed 1.28x.
| Aptus Pharma IPO | Earkart IPO | |
|---|---|---|
| QIB (times) | 1.24x | |
| NII (times) | 28.75x | 2.20x |
| Big NII (times) | 30.64x | |
| Small NII (times) | 24.93x | |
| RII (times) | 31.43x | 0.35x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 22.27x | 1.28x |
